R-2487 in Patients With Sjogren's Syndrome (SS)

Summary

The goal of this study is to determine the safety and tolerability of orally taken probiotic (R-2487) in patients with Sjogren's Syndrome. Patients will take an oral dosage of probiotic (R-2487) and physicians will assess and measure their Sjogren's Syndrome. Blood and fecal evaluations of inflammation and assessment of probiotic (R-2487) on fecal level will also be measured.

Timeline

Start

2026-06-01

Primary completion

2028-08-30

Completion

2028-08-30

Drugs

Indications